755 related articles for article (PubMed ID: 35154159)
1. Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy.
Marty PK; Van Keulen VP; Erskine CL; Shah M; Hummel A; Stachowitz M; Fatis S; Granger D; Block MS; Duarte-García A; Warrington KJ; Theel ES; Zhou X; Zeng H; Specks U; Escalante P; Peikert T
Front Immunol; 2022; 13():834981. PubMed ID: 35154159
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
[TBL] [Abstract][Full Text] [Related]
3. Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections.
Egri N; Calderón H; Martinez R; Vazquez M; Gómez-Caverzaschi V; Pascal M; Araújo O; Juan M; González-Navarro EA; Hernández-Rodríguez J
Front Immunol; 2023; 14():1146841. PubMed ID: 37180097
[TBL] [Abstract][Full Text] [Related]
4. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
5. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.
Gadani SP; Reyes-Mantilla M; Jank L; Harris S; Douglas M; Smith MD; Calabresi PA; Mowry EM; Fitzgerald KC; Bhargava P
EBioMedicine; 2021 Nov; 73():103636. PubMed ID: 34666226
[TBL] [Abstract][Full Text] [Related]
6. Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab.
Brill L; Rechtman A; Zveik O; Haham N; Oiknine-Djian E; Wolf DG; Levin N; Raposo C; Vaknin-Dembinsky A
JAMA Neurol; 2021 Dec; 78(12):1510-1514. PubMed ID: 34554197
[TBL] [Abstract][Full Text] [Related]
7. Humoral and Cellular Immune Responses to SARS-CoV-2 Infection and Vaccination in Autoimmune Disease Patients With B Cell Depletion.
Simon D; Tascilar K; Schmidt K; Manger B; Weckwerth L; Sokolova M; Bucci L; Fagni F; Manger K; Schuch F; Ronneberger M; Hueber A; Steffen U; Mielenz D; Herrmann M; Harrer T; Kleyer A; Krönke G; Schett G
Arthritis Rheumatol; 2022 Jan; 74(1):33-37. PubMed ID: 34196506
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency.
Arroyo-Sánchez D; Cabrera-Marante O; Laguna-Goya R; Almendro-Vázquez P; Carretero O; Gil-Etayo FJ; Suàrez-Fernández P; Pérez-Romero P; Rodríguez de Frías E; Serrano A; Allende LM; Pleguezuelo D; Paz-Artal E
J Clin Immunol; 2022 Feb; 42(2):240-252. PubMed ID: 34787773
[TBL] [Abstract][Full Text] [Related]
9. Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression.
Prendecki M; Clarke C; Edwards H; McIntyre S; Mortimer P; Gleeson S; Martin P; Thomson T; Randell P; Shah A; Singanayagam A; Lightstone L; Cox A; Kelleher P; Willicombe M; McAdoo SP
Ann Rheum Dis; 2021 Oct; 80(10):1322-1329. PubMed ID: 34362747
[TBL] [Abstract][Full Text] [Related]
10. Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'.
Westhoff TH; Seibert FS; Anft M; Blazquez-Navarro A; Skrzypczyk S; Doevelaar A; Hölzer B; Paniskaki K; Dolff S; Wilde B; Witzke O; Braun J; Stervbo U; Babel N
Ann Rheum Dis; 2021 Oct; 80(10):e162. PubMed ID: 34272253
[No Abstract] [Full Text] [Related]
11. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
Front Immunol; 2021; 12():726960. PubMed ID: 34671348
[TBL] [Abstract][Full Text] [Related]
12. Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease.
Malipiero G; Moratto A; Infantino M; D'Agaro P; Piscianz E; Manfredi M; Grossi V; Benvenuti E; Bulgaresi M; Benucci M; Villalta D
Immunol Res; 2021 Dec; 69(6):576-583. PubMed ID: 34417958
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.
Bonelli MM; Mrak D; Perkmann T; Haslacher H; Aletaha D
Ann Rheum Dis; 2021 Oct; 80(10):1355-1356. PubMed ID: 33958323
[No Abstract] [Full Text] [Related]
14. Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients.
Broseta JJ; Rodríguez-Espinosa D; Rodríguez N; Mosquera MDM; Marcos MÁ; Egri N; Pascal M; Soruco E; Bedini JL; Bayés B; Maduell F
Am J Kidney Dis; 2021 Oct; 78(4):571-581. PubMed ID: 34174364
[TBL] [Abstract][Full Text] [Related]
15. B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab.
Stefanski AL; Rincon-Arevalo H; Schrezenmeier E; Karberg K; Szelinski F; Ritter J; Jahrsdörfer B; Schrezenmeier H; Ludwig C; Sattler A; Kotsch K; Chen Y; Claußnitzer A; Haibel H; Proft F; Guerra G; Durek P; Heinrich F; Ferreira-Gomes M; Burmester GR; Radbruch A; Mashreghi MF; Lino AC; Dörner T
Arthritis Rheumatol; 2022 Jun; 74(6):934-947. PubMed ID: 34962360
[TBL] [Abstract][Full Text] [Related]
16. Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19.
Lozano-Rodríguez R; Valentín-Quiroga J; Avendaño-Ortiz J; Martín-Quirós A; Pascual-Iglesias A; Terrón-Arcos V; Montalbán-Hernández K; Casalvilla-Dueñas JC; Bergón-Gutiérrez M; Alcamí J; García-Pérez J; Cascajero A; García-Garrido MÁ; Balzo-Castillo ÁD; Peinado M; Gómez L; Llorente-Fernández I; Martín-Miguel G; Herrero-Benito C; Benito JM; Rallón N; Vela-Olmo C; López-Morejón L; Cubillos-Zapata C; Aguirre LA; Fresno CD; López-Collazo E
Cell Rep; 2022 Jan; 38(2):110235. PubMed ID: 34986327
[TBL] [Abstract][Full Text] [Related]
17. Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies.
Amodio D; Ruggiero A; Sgrulletti M; Pighi C; Cotugno N; Medri C; Morrocchi E; Colagrossi L; Russo C; Zaffina S; Di Matteo G; Cifaldi C; Di Cesare S; Rivalta B; Pacillo L; Santilli V; Giancotta C; Manno EC; Ciofi Degli Atti M; Raponi M; Rossi P; Finocchi A; Cancrini C; Perno CF; Moschese V; Palma P
Front Immunol; 2021; 12():727850. PubMed ID: 34671350
[TBL] [Abstract][Full Text] [Related]
18. B Cell Depletion and SARS-CoV-2 Vaccine Responses in Neuroimmunologic Patients.
Kornek B; Leutmezer F; Rommer PS; Koblischke M; Schneider L; Haslacher H; Thalhammer R; Zimprich F; Zulehner G; Bsteh G; Dal-Bianco A; Rinner W; Zebenholzer K; Wimmer I; Steinmaurer A; Graninger M; Mayer M; Roedl K; Berger T; Winkler S; Aberle JH; Tobudic S
Ann Neurol; 2022 Mar; 91(3):342-352. PubMed ID: 35067959
[TBL] [Abstract][Full Text] [Related]
19. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.
Zollner A; Watschinger C; Rössler A; Farcet MR; Penner A; Böhm V; Kiechl SJ; Stampfel G; Hintenberger R; Tilg H; Koch R; Antlanger M; Kreil TR; Kimpel J; Moschen AR
EBioMedicine; 2021 Aug; 70():103539. PubMed ID: 34391087
[TBL] [Abstract][Full Text] [Related]
20. Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab.
Nytrova P; Stastna D; Tesar A; Menkyova I; Posova H; Koprivova H; Mikulova V; Hrdy J; Smela G; Horakova D; Rysankova I; Doleckova K; Tyblova M
Front Immunol; 2023; 14():1149629. PubMed ID: 37398654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
